Skip Navigation

Patrick Y. Wen, MD


Neuro-oncology

Make an Appointment
Watch Video

Physician

  • Director, Center for Neuro-Oncology
  • Institute Physician
  • Professor of Neurology, Harvard Medical School

Centers/Programs

Clinical Interests

  • Brain and leptomeningeal metastases
  • Neurologic complications in cancer patients
  • Paraneoplastic syndromes
  • Primary brain and spinal cord tumors including gliomas, glioblastoma, primary CNS lymphoma, and ependymoma

Diseases Treated

  • Brain Metastasis
  • Brain Tumors
  • Glioblastoma
  • Low-Grade Glioma
  • Lymphoma, Primary CNS
  • Meningioma

Contact Information

  • Appointments617-632-2166
  • Office Phone Number617-632-2166
  • Fax617-632-4773

Bio

Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.

Board Certification:

  • Neurology, 1989
  • Neuro-Oncology

Fellowship:

  • Harvard Medical School, Neurology

Residency:

  • Harvard-Longwood Neurology Training Program, Neurology
  • University of London, Internal Medicine

Medical School:

  • University of London

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Shields Warren 430 D
Boston MA, 02215
Get Directions

Research

Novel Therapies For Adult Brain Tumors

The primary goal of our multidisciplinary group of investigators is to find more effective treatments for patients with brain tumors. Our program is especially interested in the development of novel targeted molecular therapies. We currently have a large number of clinical trials of these agents in progress. Recently we also started trials of combinations of targeted molecular agents, which are likely to be more effective than treatment with single agents alone. As part of these trials, we are also genotyping the tumors and correlating them with response to treatment in the hope of identifying subgroups of patients who are particularly likely to benefit. In addition, we are conducting clinical trials evaluating novel inhibitors of angiogenesis, chemotherapy combinations, intratumoral agents delivered by convection, and tumor vaccines.

A second focus of our program is the development of novel therapies for meningiomas, brain metastases, and leptomeningeal metastases; clinical studies evaluating targeted molecular agents and novel chemotherapeutic agents against these cancers are under way. We also collaborate with colleagues in Pediatric Neuro-Oncology and the Department of Cancer Biology in a preclinical program directed at identifying novel targets for therapy and evaluating new agents for clinical trials.

In addition, our program has a strong interest in quality-of-life issues affecting patients with brain tumors, in particular, venous thromboembolic disease. We are currently studying the molecular basis of venous thromboembolism and evaluating the benefit of prophylactic anticoagulation. Furthermore, we are about to begin studies evaluating the role of prophylactic anticonvulsants in patients with malignant glioma who have not had seizures and medications such as methylphenidate for radiation-induced fatigue.

Top